By extending clinical resource into the community, we help protect standards, improve access and maintain continuity of care
The Cochrane database of systematic reviews
Nonarteritic anterior ischemic optic neuropathy (NAION) is a serious eye condition characterized by sudden vision loss due to impaired blood flow to the optic nerve
[1] [2] This triple-receptor mechanism distinguishes it from currently approved agents such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GIP/GLP-1 agonist)
For those on GLP-1s, this can trigger unwanted symptoms
Key timing considerations: Side effect profile tends to be somewhat milder than semaglutide, which may reduce the importance of sleep-through timing Same 48-hour minimum spacing rule applies if changing injection days Pre-filled pen format means no reconstitution time, making spontaneous timing adjustments easier Many dulaglutide users report minimal side effects after the first month, at which point timing becomes purely a convenience decision Retatrutide (weekly injectable, investigational) Dosing frequency: Once weekly Half-life: Data from Phase 2 trials suggest approximately 6 days Peak concentration: Approximately 24 to 72 hours after injection Recommended timing approach: As a triple agonist (GLP-1/GIP/glucagon), retatrutide may produce a different side effect profile than pure GLP-1 or dual GLP-1/GIP agonists